Company Overview - Medtronic is one of the world's largest medical device companies with a diversified portfolio across cardiovascular, neuroscience, and medical-surgical sectors [2] - The company is planning to spin off its diabetes business to refocus on its highest-profit and fastest-growing operations, indicating a strategic shift [2] Innovation and Growth - Medtronic has a proven track record of innovation, exemplified by the Hugo surgical robot, which positions the company in a fast-growing medical market [4] - The company is expected to see revenue growth of 5.5% in fiscal 2026, reflecting its strategic focus on growth [7] Dividend Performance - Medtronic has achieved 48 consecutive annual dividend increases, nearing the status of Dividend Kings, which signifies a strong and reliable business model [5] - The current dividend yield is approximately 2.92%, which is historically high, indicating the company's commitment to returning value to shareholders [7] Market Position - Medtronic has a market capitalization of $124 billion, with a gross margin of 67.46%, showcasing its financial strength [7] - The stock price currently stands at $96.88, with a day's range between $96.46 and $97.86, reflecting market activity [7]

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Medtronic will lay off 81 employees from a facility in Northridge, California, that works on diabetes devices, according to a state Worker Adjustment and Retraining Notification notice, filed Feb. 5. The cuts will go into effect on April 7. Medtronic does not plan to close the entire facility, but to restructure certain operations, according to a WARN letter. The af ...

Medtronic PLC (NYSE:MDT) posted better-than-expected earnings for the third quarter on Tuesday.The company posted adjusted EPS of $1.36, beating market estimates of $1.33. The company’s quarterly sales came in at $9.017 billion, versus expectations of $8.905 billion.Medtronic affirmed its FY2026 adjusted EPS guidance of $5.62-$5.66, versus market estimates of $5.65.Medtronic shares rose 0.1% to $96.45 in pre-market trading.These analysts made changes to their price targets on Medtronic following earnings an ...

2月，全球医疗科技巨头美敦力在手术机器人领域投下两颗"重磅炸弹"。一周之内，公司相继宣布其脊柱机 器人平台 Stealth AXiS 获FDA许可、软组织机器人 Hugo RAS系统 在美国完成首批商业手术。 这一密集布局不仅彰显了其技术整合能力，也意味着手术机器人行业的竞争维度正在发生变化：从早期围绕 单一设备的功能参数比拼，逐步转向系统整合能力与数据闭环能力的综合较量。 01. 软组织战线：Hugo的商业化破局与差异化突围 一边是Stealth AXiS在骨科红海中的技术深耕，一边是Hugo系统对传统霸主直觉外科的正面突袭。美敦力正 在用"双线并进"的方式，重新划定手术机器人的竞争版图。 2月17日，克利夫兰诊所成功完成美国首例Hugo机器人辅助前列腺切除术，患者次日出院。这一案例的标杆 意义在于：它证明了Hugo不仅具备在顶级医疗机构落地的能力，更承载着美敦力对个性化医疗的诠释。 脊柱战线：从"静态定位"到"动态感知"的进化 2月13日获批的Stealth AXiS系统，并非美敦力在脊柱机器人领域的试水之作。早在2018年，其通过收购 Mazor Robotics并推出Mazor X Stealth E ...

Group 1 - Medtronic's stock is experiencing a reversal characterized by a Head & Shoulders Pattern, breaking to new highs and confirming a critical pivot point [3][5] - The stock's upward movement is supported by an improving growth outlook, profitability, capital return, and positive market sentiment, with a solid support base expected in 2026 [3][5] - Institutions own over 80% of Medtronic's stock and have been accumulating shares for several quarters, indicating strong bullish sentiment [6] Group 2 - Analysts rate Medtronic as a Moderate Buy, with increasing coverage and a bullish price target trend ahead of the fiscal Q3 release [7] - The consensus forecast suggests a 10% upside, with potential for another 10% at the high end, aligning with the stock's upward trajectory [7] - Technical targets indicate that Medtronic's stock could reach a range of $118-$124, with the possibility of this movement occurring before mid-year [8]

Core Viewpoint - Medtronic plc reported fiscal third-quarter 2026 results that exceeded analyst expectations, although shares experienced a decline of over 2% intra-day following the release [1] Financial Performance - The company generated revenue of $9.0 billion, reflecting an 8.7% increase on a reported basis and 6.0% organic growth year over year, surpassing the consensus estimate of $8.89 billion [2] - Adjusted earnings per share were reported at $1.36, slightly above expectations of $1.34 [2] - The quarter marked the strongest enterprise revenue growth for the company in 10 quarters [2] Segment Performance - The Cardiovascular Portfolio led the performance with revenue climbing 13.8% as reported and 10.6% organically to $3.46 billion, with Cardiac Ablation Solutions showing particularly strong results, including an 80% increase in global revenue and a 137% surge in U.S. revenue [3] - Other segments also reported gains: the Neuroscience Portfolio increased 4.1% to $2.56 billion, the Medical Surgical Portfolio rose 4.9% to $2.17 billion, and the Diabetes segment grew 14.8% to $796 million [4] Outlook - Medtronic reaffirmed its fiscal 2026 outlook, maintaining expectations for approximately 5.5% organic revenue growth and adjusted EPS between $5.62 and $5.66, which includes a potential $185 million headwind from tariffs [4]

Paramount, Masimo, Medtronic, Kyndryl, eToro, Genuine Parts, Southwest, and More Movers - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# These Stocks Are Today's Movers: Paramount, Masimo, Medtronic, Kyndryl, eToro, Genuine Parts, Southwest, ...

Core Insights - Medtronic reported adjusted earnings of $1.36 per share, surpassing expectations of $1.33 [1] Segment Performance - Neuroscience Portfolio revenue reached $2.558 billion, reflecting a 4.1% increase reported and 2.5% organic growth, with mid-single digit increases in Neuromodulation and Cranial & Spinal Technologies, while Specialty Therapies remained flat on an organic basis [2] - Medical Surgical Portfolio revenue was $2.173 billion, marking a 4.9% increase as reported and 2.7% organic growth, driven by low-single digit growth in Surgical & Endoscopy and high-single digit growth in Acute Care & Monitoring on an organic basis [2] - Diabetes business revenue amounted to $796 million, showing a significant increase of 14.8% reported and 8.3% organic growth [2] Financial Outlook - Medtronic reiterated its fiscal 2026 organic revenue growth target of approximately 5.5% and adjusted earnings per share guidance of $5.62 to $5.66, which includes a potential tariff impact of about $185 million [4] - Excluding the tariff impact, the guidance indicates an adjusted EPS growth of approximately 4.5% for fiscal 2026 [4] Strategic Initiatives - The company emphasized its commitment to investing in R&D to enhance its innovation pipeline and executed two key transactions in the quarter as part of its M&A and venture strategy [5] - Medtronic announced its decision to acquire CathWorks, a privately held medical device company in Israel, with the acquisition valued at up to $585 million, including potential undisclosed earn-out payments [6]

Core Insights - Medtronic has launched a direct-to-consumer "Go Beyond" campaign, resulting in a significant increase in website traffic, with visits rising from approximately 50,000 to 2.5 million [1] - The company is focusing on scaling its Symplicity platform for renal denervation, targeting the 18 million patients in the U.S. with uncontrolled hypertension [2] - Medtronic's management highlighted strong growth in various product areas, including cardiovascular and diabetes segments, while reiterating financial guidance for fiscal 2026 and expectations for high single-digit adjusted EPS growth in fiscal 2027 [4][5] Product and Market Developments - The cardiovascular portfolio revenue grew 11% year-over-year, with a notable 80% growth in cardiac ablation systems (CAS), driven by pulsed field ablation (PFA) [12] - The MiniMed diabetes business reported a 15% increase in revenue, with significant growth attributed to international markets and new product launches [16] - Medtronic is scaling its Symplicity Spyral and Altaviva platforms, with early traction observed in patient referrals and physician training [6] Financial Performance - Medtronic reported revenue of $9.0 billion for the quarter, reflecting an 8.7% increase, with adjusted gross margin at 64.9% [5][17] - Adjusted operating profit reached $2.2 billion, with an adjusted operating margin of 24.1%, exceeding expectations [18] - The company maintained its fiscal 2026 organic revenue growth guidance of approximately 5.5% and adjusted EPS guidance of $5.62 to $5.66 [19] Regulatory and Technological Advancements - The Hugo robotic-assisted surgery system received FDA clearance for urologic procedures, marking the beginning of its U.S. launch [7] - The Stealth Access Surgical System for spinal procedures was also cleared by the FDA, integrating AI-powered planning and robotics [10][11] - Medtronic's Touch Surgery digital ecosystem installations surpassed 1,000 globally, showcasing a 20% sequential growth [8]

Market Overview - The US stock market experienced a decline, with the Dow Jones Industrial Average falling 114.78 points to 49,386.15, the S&P 500 dropping 16.85 points to 6,819.32, and the Nasdaq Composite declining 78.52 points to 22,468.15 [1][26] - This decline marks continued weakness, with the Dow and S&P 500 down in four of the past five weeks [1][26] Investor Sentiment - Concerns about artificial intelligence disrupting major industries, falling oil prices following Iran-US nuclear talks, and uncertainty regarding Federal Reserve rate cuts have negatively impacted investor sentiment [2][26] - The earnings season is nearing its end, with significant corporate reports from Walmart, Constellation Energy, Medtronic, and Palo Alto Networks being closely monitored [2][26] AI and Industry Impact - Investors are increasingly questioning how artificial intelligence will reshape various industries, including wealth management, transportation, logistics, and energy [5][26] - The uncertainty surrounding AI has led to profit-taking across technology and growth stocks, contributing to a 0.35% decline in the Nasdaq and a 0.25% loss in the S&P 500 [8][26] Earnings Reports - Constellation Energy's results are being watched for insights into how AI-driven data center demand is affecting electricity consumption [9][26] - Walmart's upcoming quarterly earnings report is critical as it is the company's first update since reaching a trillion-dollar market cap, with investors focusing on consumer spending trends [11][26] Commodity Market - Commodity markets are experiencing heavy selling pressure, with WTI crude oil down 1.05% to $62.23 and Brent crude declining 0.74% to $66.11 [16][27] - The decline in oil prices may ease inflation concerns but also signals potential demand worries [27] Cryptocurrency Market - The cryptocurrency market is also facing declines, with Bitcoin falling 2.19% to $67,326 and the Nasdaq Crypto Index losing 1.91% to 3,255.42, reflecting a broad-based weakness across digital assets [21][27] Economic Indicators - Upcoming economic data, including the Personal Consumption Expenditures (PCE) inflation index and fourth-quarter GDP, could significantly influence market movements [3][22] - A new analysis from Bank of America highlights a "K-shaped economy," where corporate profits are rising while labor income is falling, indicating potential long-term pressures on consumer spending [24][26]